Oeppen, J. & Vaupel, J. W. Demography. Broken limits to life expectancy. Science 296, 1029–1031 (2002).
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J. & Kirkland, J. L. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J. Clin. Invest. 123, 966–972 (2013).
Bluher, M. Obesity: global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 15, 288–298 (2019).
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O. & Heikenwalder, M. From NASH to HCC: current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 16, 411–428 (2019).
Gallage, S. et al. The therapeutic landscape of hepatocellular carcinoma. Med 2, 505–552 (2021).
Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J. Hepatol. 69, 896–904 (2018).
Younossi, Z. et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology 69, 2672–2682 (2019).
Huang, D. Q., El-Serag, H. B. & Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18, 223–238 (2021).
Huang, D. Q. et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. https://doi.org/10.1016/j.cmet.2022.05.003 (2022).
Dudek, M. et al. Auto-aggressive CXCR6+ CD8+ T cells cause liver immune pathology in NASH. Nature 592, 444–449 (2021).
Leslie, J. et al. CXCR2 inhibition enables NASH–HCC immunotherapy. Gut https://doi.org/10.1136/gutjnl-2021-326259 (2022).
Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450–456 (2021). This paper demonstrates that anti-PD-1 immunotherapy is not effective against NASH-induced HCC in mouse NASH models.
Wabitsch, S. et al. Metformin treatment rescues CD8+ T cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J. Hepatol. https://doi.org/10.1016/j.jhep.2022.03.010 (2022). This paper shows that metformin treatment cansensitize NASH-induced HCCs to anti-PD-1 immunotherapy in preclinical mouse models.
Anstee, Q. M. & Goldin, R. D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J. Exp. Pathol. 87, 1–16 (2006).
Oligschlaeger, Y. & Shiri-Sverdlov, R. NAFLD Preclinical models: more than a handful, less of a concern? Biomedicines https://doi.org/10.3390/biomedicines8020028 (2020).
Santhekadur, P. K., Kumar, D. P. & Sanyal, A. J. Preclinical models of non-alcoholic fatty liver disease. J. Hepatol. 68, 230–237 (2018).
Febbraio, M. A. et al. Preclinical models for studying NASH-driven HCC: how useful are they. Cell Metab. 29, 18–26 (2019).
Farrell, G. et al. Mouse models of non-alcoholic steatohepatitis: toward optimization of their relevance to human non-alcoholic steatohepatitis. Hepatology 69, 2241–2257 (2019).
Haczeyni, F. et al. Mouse models of non-alcoholic steatohepatitis: a reflection on recent literature. J. Gastroenterol. Hepatol. 33, 1312–1320 (2018).
Mann, J. P., Semple, R. K. & Armstrong, M. J. How useful are monogenic rodent models for the study of human non-alcoholic fatty liver disease? Front Endocrinol. 7, 145 (2016).
Brunt, E. M. et al. Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD. J. Hepatol. 76, 1030–1041 (2022). This paper i llustrates the difficulty in identifying ballooned hepatocytes even by expert histopathologists and the potential of AI imaging.
Ramos, M. J., Bandiera, L., Menolascina, F. & Fallowfield, J. A. In vitro models for non-alcoholic fatty liver disease: emerging platforms and their applications. iScience 25, 103549 (2022).
Ströbel, S. et al. A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates. Sci. Rep. 11, 22765 (2021).
Bissig-Choisat, B. et al. A human liver chimeric mouse model for non-alcoholic fatty liver disease. JHEP Rep. 3, 100281 (2021).
Ma, J. et al. A novel humanized model of NASH and its treatment with META4, a potent agonist of MET. Cell Mol. Gastroenterol. Hepatol. 13, 565–582 (2022). The authors of this study developed a novel humanized model of NASH withhuman hepatocytes.
Gallage, S. et al. Spontaneous cholemia in C57BL/6 mice predisposes to liver cancer in NASH. Cell Mol. Gastroenterol. Hepatol. 13, 875–878 (2022). This paper demonstrates that a subset of all C57BL/6 mice from either commercial breeders or inbred strains shows spontaneous cholaemia that can predispose them to liver cancer following high-caloric feeding.
Glode, L. M. & Rosenstreich, D. L. Genetic control of B cell activation by bacterial lipopolysaccharide is mediated by multiple distinct genes or alleles. J. Immunol. 117, 2061–2066 (1976).
Fan, R., Wang, J. & Du, J. Association between body mass index and fatty liver risk: a dose-response analysis. Sci. Rep. 8, 15273 (2018).
Im, Y. R. et al. A systematic review of animal models of NAFLD finds high-fat, high-fructose diets most closely resemble human NAFLD. Hepatology 74, 1884–1901 (2021).
Trevaskis, J. L. et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of non-alcoholic steatohepatitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G762–G772 (2012).
Clapper, J. R. et al. Diet-induced mouse model of fatty liver disease and non-alcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am. J. Physiol. Gastrointest. Liver Physiol. 305, G483–G495 (2013). The authors developed the AMLN Western-diet mouse model of NASH.
Radhakrishnan, S., Yeung, S. F., Ke, J. Y., Antunes, M. M. & Pellizzon, M. A. Considerations when choosing high-fat, high-fructose and high-cholesterol diets to induce experimental non-alcoholic fatty liver disease in laboratory animal models. Curr. Dev. Nutr. 5, nzab138 (2021).
Boland, M. L. et al. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: impact of dietary fat source. World J. Gastroenterol. 25, 4904–4920 (2019). The authors developed the GAN Western-diet mouse model of NASH.
Hansen, H. H. et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol. 20, 210 (2020).
Mollerhoj, M. B. et al. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH. Clin. Transl. Sci. 15, 1167–1186 (2022).
Drescher, H. K. et al. The influence of different fat sources on steatohepatitis and fibrosis development in the Western diet mouse model of non-alcoholic steatohepatitis (NASH. Front Physiol 10, 770 (2019). This paper shows the validity of theWestern diet NTF mouse model of NASH.
The Jackson Laboratory. C57BL/6J mice https://www.jax.org/strain/000664 (2022).
Eng, J. M. & Estall, J. L. Diet-induced models of non-alcoholic fatty liver disease: food for thought on sugar, fat and cholesterol. Cells https://doi.org/10.3390/cells10071805 (2021).
Chen, H. et al. Consumption of sugar-sweetened beverages has a dose-dependent effect on the risk of non-alcoholic fatty liver disease: an updated systematic review and dose-response meta-analysis. Int. J. Environ. Res. Public Health https://doi.org/10.3390/ijerph16122192 (2019).
Zelber-Sagi, S. et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J. Hepatol. 47, 711–717 (2007).
Togo, J., Hu, S., Li, M., Niu, C. & Speakman, J. R. Impact of dietary sucrose on adiposity and glucose homeostasis in C57BL/6J mice depends on mode of ingestion: liquid or solid. Mol. Metab. 27, 22–32 (2019).
Mastrocola, R. et al. Fructose liquid and solid formulations differently affect gut integrity, microbiota composition and related liver toxicity: a comparative in vivo study. J. Nutr. Biochem. 55, 185–199 (2018).
Khitan, Z. & Kim, D. H. Fructose: a key factor in the development of metabolic syndrome and hypertension. J. Nutr. Metab. 2013, 682673 (2013).
Febbraio, M. A. & Karin, M. ‘Sweet death’: fructose as a metabolic toxin that targets the gut–liver axis. Cell Metab. 33, 2316–2328 (2021).
Jensen, T. et al. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. J. Hepatol. 68, 1063–1075 (2018).
Todoric, J. et al. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat. Metab. 2, 1034–1045 (2020).
Ioannou, G. N. et al. Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH. J. Lipid Res. 58, 1067–1079 (2017).
Van Rooyen, D. M. et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes non-alcoholic steatohepatitis. Gastroenterology 141, 1393–1403 (2011).
Van Rooyen, D. M. et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J. Hepatol. 59, 144–152 (2013).
Zhang, X. et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut 70, 761–774 (2021). This study demonstrates that a low-cholesterol Western diet does not induce spontaneous NASH–HCC in C57BL/6 mice.
Asgharpour, A. et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J. Hepatol. 65, 579–588 (2016). The authors developed the DIAMOND model of NASH–HCC in the mixed B6/129 strain.
Wolf, M. J. et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes non-alcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26, 549–564 (2014). The authors developed the CDHFD model of NASH and NASH–HCC in C57BL/6 mice.
Grohmann, M. et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell 175, 1289–1306 (2018).
Kishida, N. et al. Development of a novel mouse model of hepatocellular carcinoma with non-alcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine. BMC Gastroenterol. 16, 61 (2016).
Malehmir, M. et al. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat. Med. 25, 641–655 (2019).
Smati, S. et al. Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target. Gut 71, 807–821 (2022).
Yao, Z. M. & Vance, D. E. The active synthesis of phosphatidylcholine is required for very-low-density lipoprotein secretion from rat hepatocytes. J. Biol. Chem. 263, 2998–3004 (1988).
Ashworth, C. T., Sanders, E. & Arnold, N. Hepatic lipids; fine structural changes in liver cells after high-fat, high-cholesterol, and choline-deficient diets in rats. Arch. Pathol. 72, 625–636 (1961).
Salaspuro, M. P. & Mäenpää, P. H. Influence of ethanol on the metabolism of perfused normal, fatty and cirrhotic rat livers. Biochem. J. 100, 768–778 (1966).
Kalhan, S. C. et al. Plasma metabolomic profile in non-alcoholic fatty liver disease. Metabolism 60, 404–413 (2011).
Ikawa-Yoshida, A. et al. Hepatocellular carcinoma in a mouse model fed a choline-deficient, l-amino acid-defined, high-fat diet. Int. J. Exp. Pathol. 98, 221–233 (2017). The authors developed the CDAHFD model of NASH–HCC in lean mice.
Matsumoto, M. et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int. J. Exp. Pathol. 94, 93–103 (2013). The authors developed the CDAHFD model of NASH in lean mice.
Lee, C. et al. Formyl peptide receptor 2 determines sex-specific differences in the progression of non-alcoholic fatty liver disease and steatohepatitis. Nat. Commun. 13, 578 (2022).
Suzuki-Kemuriyama, N. et al. Nonobese mice with non-alcoholic steatohepatitis fed on a choline-deficient, l-amino acid-defined, high-fat diet exhibit alterations in signaling pathways. FEBS Open Bio 11, 2950–2965 (2021).
Albhaisi, S., Chowdhury, A. & Sanyal, A. J. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 1, 329–341 (2019).
Tetri, L. H., Basaranoglu, M., Brunt, E. M., Yerian, L. M. & Neuschwander-Tetri, B. A. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G987–G995 (2008). The authors developed the ALIOS model of NASH in mice.
Harris, S. E. et al. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of no-nalcoholic fatty liver disease and non-alcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 319, G345–G360 (2020).
Itagaki, H., Shimizu, K., Morikawa, S., Ogawa, K. & Ezaki, T. Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice. Int. J. Clin. Exp. Pathol. 6, 2683–2696 (2013).
Gautheron, J. et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol. Med. 6, 1062–1074 (2014).
Ma, C. et al. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531, 253–257 (2016).
Jha, P. et al. Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH). Biochim. Biophys. Acta 1842, 959–970 (2014).
Rinella, M. E. & Green, R. M. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J. Hepatol. 40, 47–51 (2004).
Leclercq, I. A., Farrell, G. C., Sempoux, C., dela Peña, A. & Horsmans, Y. Curcumin inhibits NF-κB activation and reduces the severity of experimental steatohepatitis in mice. J. Hepatol. 41, 926–934 (2004).
Ramadori, P., Weiskirchen, R., Trebicka, J. & Streetz, K. Mouse models of metabolic liver injury. Lab. Anim. 49, 47–58 (2015).
Fontaine, D. A. & Davis, D. B. Attention to background strain is essential for metabolic research: C57BL/6 and the International Knockout Mouse Consortium. Diabetes 65, 25–33 (2016).
Champy, M. F. et al. Genetic background determines metabolic phenotypes in the mouse. Mamm. Genome 19, 318–331 (2008).
Mekada, K. et al. Genetic differences among C57BL/6 substrains. Exp. Anim. 58, 141–149 (2009).
Simon, M. M. et al. A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains. Genome Biol. 14, R82 (2013).
Green, C. D. et al. A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. FASEB J. https://doi.org/10.1096/fj.202200346R (2022). This paper shows that a Western diet with sugar water can induce NASH and NASH–HCC in C57BL/6N mice.
Arsov, T. et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem. Biophys. Res. Commun. 342, 1152–1159 (2006).
Arsov, T. et al. Fat aussie–a new Alström syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis. Mol. Endocrinol. 20, 1610–1622 (2006).
Larter, C. Z. et al. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J. Gastroenterol. Hepatol. 24, 1658–1668 (2009).
Ganguly, S. et al. non-alcoholic steatohepatitis and HCC in a hyperphagic mouse accelerated by Western diet. Cell Mol. Gastroenterol. Hepatol. 12, 891–920 (2021). Foz/Foz mice were fed a Western diet to induce NASH and subsequent NASH–HCC.
Nakagawa, H. et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 26, 331–343 (2014). This study developed the MUP-uPA model of NASH and NASH–HCC.
Shalapour, S. et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551, 340–345 (2017).
Fujii, M. et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med. Mol. Morphol. 46, 141–152 (2013).
Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197–208 (2010). This paper shows that obesity promotes liver carcinogenesis.
Liu, F. et al. Long non-coding RNA SNHG6 couples cholesterol sensing with mTORC1 activation in hepatocellular carcinoma. Nat. Metab. 4, 1022–1040 (2022).
Ge, C. et al. Hepatocyte phosphatase DUSP22 mitigates NASH–HCC progression by targeting FAK. Nat. Commun. 13, 5945 (2022).
Tsuchida, T. et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J. Hepatol. 69, 385–395 (2018). The authors developed an accelerated model of NASH and NASH–HCC with profound fibrosis by combining a Western diet with weekly CCl4 injections.
Horie, Y. et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 113, 1774–1783 (2004). This paper shows that hepatocyte-specific deletion of Pten results in NASH and subsequent liver cancer.
Stiles, B. et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. Proc. Natl Acad. Sci. USA 101, 2082–2087 (2004).
Ortega-Molina, A. & Serrano, M. PTEN in cancer, metabolism, and aging. Trends Endocrinol. Metab. 24, 184–189 (2013).
Panasyuk, G. et al. PPARγ contributes to PKM2 and HK2 expression in fatty liver. Nat. Commun. 3, 672 (2012).
Peyrou, M. et al. Hepatic PTEN deficiency improves muscle insulin sensitivity and decreases adiposity in mice. J. Hepatol. 62, 421–429 (2015).
Langford, C. R. et al. Improved pathology reporting in NAFLD/NASH for clinical trials. J. Clin. Pathol. 75, 73–75 (2022).
Kleiner, D. E. et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005). The authors designed the NAS to assess the histopathology of liver tissue.
Brunt, E. M. et al. NAFLD: reporting histologic findings in clinical practice. Hepatology 73, 2028–2038 (2021).
Ahn, J. C., Connell, A., Simonetto, D. A., Hughes, C. & Shah, V. H. Application of artificial intelligence for the diagnosis and treatment of liver diseases. Hepatology 73, 2546–2563 (2021).
Soon, G. S. T. et al. Artificial intelligence improves pathologist agreement for fibrosis scores in non-alcoholic steatohepatitis patients. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2022.05.027 (2022).
Nam, D., Chapiro, J., Paradis, V., Seraphin, T. P. & Kather, J. N. Artificial intelligence in liver diseases: improving diagnostics, prognostics and response prediction. JHEP Rep. 4, 100443 (2022).
Liu, F. et al. qFIBS: an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with non-alcoholic steatohepatitis. Hepatology 71, 1953–1966 (2020).
Taylor-Weiner, A. et al. A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH. Hepatology 74, 133–147 (2021).
Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with non-alcoholic fatty liver disease. Gastroenterology 149, 389–397 (2015). This study demonstrates the importance of liver fibrosis for outcomes in NASH patients.
Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65, 1557–1565 (2017).
Kingma, B. R., Frijns, A. J., Schellen, L. & van Marken Lichtenbelt, W. D. Beyond the classic thermoneutral zone: Including thermal comfort. Temp. 1, 142–149 (2014).
Škop, V. et al. Mouse thermoregulation: introducing the concept of the thermoneutral point. Cell Rep. 31, 107501 (2020).
Giles, D. A. et al. Thermoneutral housing exacerbates non-alcoholic fatty liver disease in mice and allows for sex-independent disease modeling. Nat. Med. 23, 829–838 (2017). This paper shows that thermoneutral housing can exacerbate NASH pathogenesis.
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
Burra, P. et al. Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 41, 1713–1733 (2021).
Lonardo, A. et al. Sex differences in non-alcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 70, 1457–1469 (2019).
Vandel, J. et al. Hepatic molecular signatures highlight the sexual dimorphism of non-alcoholic steatohepatitis (NASH). Hepatology 73, 920–936 (2021).
Iyer, J. K., Kalra, M., Kaul, A., Payton, M. E. & Kaul, R. Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis. World J. Gastroenterol. 23, 6802–6816 (2017).
Louet, J. F., LeMay, C. & Mauvais-Jarvis, F. Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr. Atheroscler. Rep. 6, 180–185 (2004).
Espeland, M. A. et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 21, 1589–1595 (1998).
Hassan, M. M. et al. Estrogen replacement reduces risk and increases survival times of women with hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 15, 1791–1799 (2017).
McGlynn, K. A. et al. Menopausal hormone therapy use and risk of primary liver cancer in the clinical practice research datalink. Int J. Cancer 138, 2146–2153 (2016).
McGlynn, K. A. et al. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project. Br. J. Cancer 112, 1266–1272 (2015).
McKenzie, J. et al. Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin. Endocrinol. 65, 40–44 (2006).
Nakatani, T., Roy, G., Fujimoto, N., Asahara, T. & Ito, A. Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin. Jpn. J. Cancer Res. 92, 249–256 (2001).
Le Roy, T. et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62, 1787–1794 (2013).
Moschen, A. R., Kaser, S. & Tilg, H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol. Metab. 24, 537–545 (2013).
Yoshimoto, S. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97–101 (2013). This study highlights that the secondary bile acid deoxycholic acid from gut microbiota can driveobesity-dependent liver carcinogenesis.
Yang, J. & Chun, J. Taxonomic composition and variation in the gut microbiota of laboratory mice. Mamm. Genome 32, 297–310 (2021).
Weiskirchen, S., Weiper, K., Tolba, R. H. & Weiskirchen, R. All you can feed: some comments on production of mouse diets used in biomedical research with special emphasis on non-alcoholic fatty liver disease research. Nutrients https://doi.org/10.3390/nu12010163 (2020).
Ericsson, A. C. & Franklin, C. L. The gut microbiome of laboratory mice: considerations and best practices for translational research. Mamm. Genome 32, 239–250 (2021).
Chiang, J. Y. Bile acid metabolism and signaling. Compr. Physiol. 3, 1191–1212 (2013).
Haeusler, R. A., Astiarraga, B., Camastra, S., Accili, D. & Ferrannini, E. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes 62, 4184–4191 (2013).
Prinz, P. et al. Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. Front Neurosci. 9, 199 (2015).
Sun, W. et al. Insulin resistance is associated with total bile acid level in type 2 diabetic and nondiabetic population: a cross-sectional study. Med. 95, e2778 (2016).
Sydor, S. et al. Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH–HCC. Clin. Transl. Gastroenterol. 11, e00131 (2020).
Chávez-Talavera, O., Tailleux, A., Lefebvre, P. & Staels, B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and non-alcoholic fatty liver disease. Gastroenterology 152, 1679–1694 (2017).
Cudalbu, C. et al. The C57BL/6J mouse exhibits sporadic congenital portosystemic shunts. PLoS ONE 8, e69782 (2013). This paper shows that a subset of C57BL/6 mice display portosystemic shunts that may predispose to liver pathologies.
d’Anjou, M. A., Penninck, D., Cornejo, L. & Pibarot, P. Ultrasonographic diagnosis of portosystemic shunting in dogs and cats. Vet. Radio. Ultrasound 45, 424–437 (2004).
Lemoine, C. et al. Liver histopathology in patients with hepatic masses and the Abernethy malformation. J. Pediatr. Surg. 54, 266–271 (2019).
Ronda, O. et al. Spontaneous liver disease in wild-type C57BL/6JOlaHsd mice fed semisynthetic diet. PLoS ONE 15, e0232069 (2020). This paper demonstrates that wild-type C57BL/6OlaHsd mice also show spontaneous cholaemia and can predispose to liver pathology.
Sharma, R. et al. Congenital extrahepatic portosystemic shunt complicated by the development of hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 14, 552–557 (2015).
Gastaldelli, A. & Cusi, K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep. 1, 312–328 (2019).
Korenblat, K. M., Fabbrini, E., Mohammed, B. S. & Klein, S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134, 1369–1375 (2008).
Xu, X. et al. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct. Target Ther. 7, 287 (2022).
DeFronzo, R. A., Tobin, J. D. & Andres, R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237, E214–E223 (1979).
Ayala, J. E., Lantier, L., McGuinness, O. P. & Wasserman, D. H. Peeling back the layers of the glucose clamp. Nat. Metab. 4, 496–498 (2022).
Virtue, S. & Vidal-Puig, A. GTTs and ITTs in mice: simple tests, complex answers. Nat. Metab. 3, 883–886 (2021). This paper describes the intracies of metabolic phenotyping of mice with glucose and insulin tolerance tests.
Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985).
Wallace, T. M., Levy, J. C. & Matthews, D. R. Use and abuse of HOMA modeling. Diabetes Care 27, 1487–1495 (2004).
